Subscribe 600$/product give away!
Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

AKYNZEO- netupitant and palonosetron capsuleAKYNZEO- fosnetupitant and palonosetron injection

Patient Information

Advise patients to read the FDA-approved patient labeling (Patient Information).


Advise patients to take AKYNZEO capsules with or without food approximately 1 hour prior to the start of chemotherapy[see Dosage and Administration (2.1)].

Hypersensitivity Reactions

Advise patients that hypersensitivity reactions, including anaphylaxis, may occur in patients receiving AKYNZEO. Advise patients to seek immediate medical attention if any signs or symptoms of a hypersensitivity reaction occur while taking AKYNZEO[See Warnings and Precautions (5.1)].

Serotonin Syndrome

Advise patients of the possibility of serotonin syndrome especially with concomitant use of AKYNZEO and another serotonergic agent such as medications to treat depression and migraines. Advise patients to seek immediate medical attention if the following symptoms occur: changes in mental status, autonomic instability, neuromuscular symptoms, with or without gastrointestinal symptoms[see Warnings and Precautions (5.2)].


Inform female patients of reproductive potential that AKYNZEO may cause fetal harm and to inform their prescriber of a known or suspected pregnancy[see Use in Specific Populations (8.1)].

Manufactured by Helsinn Birex Pharmaceuticals, Dublin, Ireland for Helsinn Healthcare SA, Switzerland

Distributed by Helsinn Therapeutics (U.S.), Inc., Iselin, NJ08830, under license of Helsinn Healthcare SA, Switzerland

AKYNZEO is a registered trademark of Helsinn Healthcare SA, Lugano, Switzerland

Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources | Sitemap
2017 © Copyright Questions?
Please contact: